文献速递胸部肿瘤放疗放疗物理与技术

早期肺腺癌核心活检组织学亚型是立体定向体部放疗后治疗反应与失败模式的预后因素

Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-09-29

该研究回顾了119例(124个病灶)I-IIA期肺腺癌患者接受根治性SBRT的结局,按2015年WHO分类进行组织学亚型分组,其中37个(30%)为高危亚型(含实性/微乳头成分)。高危亚型与非高危亚型相比,局部、区域和远处失败的1年累积发生率和校正HR均显著更高,但总生存无显著差异。结论认为核心活检组织学亚型是SBRT后的预后因素。

要点

  • 高危亚型(含实性/微乳头)局部失败1年累积发生率7.3% vs 2.7%,HR 16.8。
  • 高危亚型远处失败1年累积发生率22.7% vs 3.6%,HR 6.9。
  • 两组总生存无显著差异。

核心结论

  • 早期肺腺癌SBRT后结局与组织学亚型高度相关,微乳头和实性肿瘤预示显著更高的局部区域和转移进展率。
  • 核心活检确定的组织学亚型是预后因素,可能对患者选择、辅助治疗、活检方法和临床试验设计有重要影响。

研究设计与样本

  • 单中心回顾性研究,纳入2008年8月至2015年8月接受根治性SBRT的119例连续患者(124个病灶),均为I-IIA期肺腺癌且接受核心活检。
  • 按2015年WHO分类进行组织学亚型分型,37个(30%)肿瘤为高危亚型(含实性 and/or 微乳头成分)。
  • 采用Gray检验比较累积发生率,倾向评分加权Cox回归模型估计多变量校正HR。

主要发现

  • 全队列中位随访17个月,存活患者中位随访21个月。
  • 高危 vs 非高危亚型局部失败1年累积发生率7.3% vs 2.7%(HR 16.8;95%CI 3.5-81.4)。
  • 淋巴结失败1年累积发生率14.8% vs 2.6%(HR 3.8;95%CI 0.95-15.0)。
  • 区域失败1年累积发生率4.0% vs 1.2%(HR 20.9;95%CI 2.3-192.3)。
  • 远处失败1年累积发生率22.7% vs 3.6%(HR 6.9;95%CI 2.2-21.1),总生存无显著差异。

临床怎么用

  • 对早期肺腺癌拟行SBRT者,可考虑核心活检明确组织学亚型以辅助预后评估。
  • 高危亚型(含实性/微乳头)患者SBRT后局部区域和远处失败风险更高,需加强随访监测。
  • 组织学亚型信息可能影响患者选择、辅助治疗决策及临床试验设计。

局限性

  • 单中心回顾性研究,样本量有限(119例患者/124个病灶)。
  • 中位随访时间较短(全队列17个月,存活患者21个月)。
  • 部分失败结局的95%CI较宽(如区域失败HR 20.9,95%CI 2.3-192.3)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as an effective treatment for early-stage lung cancer. The histologic subtype of surgically resected lung adenocarcinoma is recognized as a prognostic factor, with the presence of solid or micropapillary patterns predicting poor outcomes. We describe the outcomes after SBRT for early-stage lung adenocarcinoma stratified by histologic subtype. METHODS AND MATERIALS: We identified 119 consecutive patients (124 lesions) with stage I to IIA lung adenocarcinoma who had undergone definitive SBRT at our institution from August 2008 to August 2015 and had undergone core biopsy. Histologic subtyping was performed according to the 2015 World Health Organization classification. Of the 124 tumors, 37 (30%) were a high-risk subtype, defined as containing a component of solid and/or micropapillary pattern. The cumulative incidences of local, nodal, regional, and distant failure were compared between the high-risk and non-high-risk adenocarcinoma subtypes using Gray's test, and multivariable-adjusted hazard ratios (HRs) were estimated from propensity score-weighted Cox regression models. RESULTS: The median follow-up for the entire cohort was 17 months and for surviving patients was 21 months. The 1-year cumulative incidence of and adjusted HR for local, nodal, regional, and distant failure in high-risk versus non-high-risk lesions was 7.3% versus 2.7% (HR 16.8; 95% confidence interval [CI] 3.5-81.4), 14.8% versus 2.6% (HR 3.8; 95% CI 0.95-15.0), 4.0% versus 1.2% (HR 20.9; 95% CI 2.3-192.3), and 22.7% versus 3.6% (HR 6.9; 95% CI 2.2-21.1), respectively. No significant difference was seen with regard to overall survival. CONCLUSIONS: The outcomes after SBRT for early-stage adenocarcinoma of the lung correlate highly with histologic subtype, with micropapillary and solid tumors portending significantly higher rates of locoregional and metastatic progression. In this context, the histologic subtype determined from core biopsies is a prognostic factor and could have important implications for patient selection, adjuvant treatment, biopsy methods, and clinical trial design.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Leeman JE, Rimner A, Montecalvo J, et al. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016. PMID: 27839909. doi:10.1016/j.ijrobp.2016.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。